Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Hospitalized COVID-19 Patients
NCT04332094Phase 2Unknown
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Apr 2020
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoints: In-hospital mortality and Need for mechanical ventilation in the Intensive Care Unit. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04332094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332094.